MedPath

EVALUATION OF PULSE OXYMETER PARAMETER TO PREDICT REQUIREMENT OF DRUGS TO INCREASE BLOOD PRESSURE IN PATIENTS WITH SEPSIS

Not yet recruiting
Conditions
Sepsis, unspecified organism,
Registration Number
CTRI/2023/02/049572
Lead Sponsor
Indraprastha Apollo Hospitals
Brief Summary

We will study patients with sepsis our pulse oxymeter derived parameter - perfusion index in observational manner as a prospective study at Indraprastha Apollo New Delhi. The patients will receive adequate fluid resuscitation (30 ml/kg) as part of sepsis treatment as per standard guidelines of care. After that perfusion index will be observed. At 6 hour interval , we will observe perfusion index again. We will follow these patients in course of stay and see for how many patients required vasopressor therapy in initial 24 hours (primary objective) and what was the outcome of patient (secondary objective).

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
35
Inclusion Criteria

Age> 18 years Clinically suspected sepsis Adequate Fluid Resuscitation (30ml/kg).

Exclusion Criteria

Age < 18 years Pregnant Females inadequate fluid resuscitation (<30ml/kg) Already receiving vasopressor therapy.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Compare perfusion index to arterial lactate levels at T0 and T6 hours as predictor of vasopressor requirement in first 24 hourCompare perfusion index to arterial lactate levels at T0 and T6 hours as predictor of vasopressor requirement in first 24 hour
Secondary Outcome Measures
NameTimeMethod
final outcome of patients with sepsis (Discharged / Death)0-28 days

Trial Locations

Locations (1)

Indraprastha Apollo Hospitals

🇮🇳

South, DELHI, India

Indraprastha Apollo Hospitals
🇮🇳South, DELHI, India
Dr Jaydeep Narendrabhai Anadkat
Principal investigator
8866487547
jaydeepanadkat@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.